Q3 FY2025 · Press release
Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2 · November 12, 2025 · 3 pages
Read Alkermes plc's results firsthand
Preview the first 2 pages of this press release
Create a free account to start reading
Full documents are included with Professional